Gender and disease duration can help predict which axial spondyloarthritis patients will develop extra-articular manifestations such as uveitis, or inflammation of the eye, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
The U.S. adult rheumatology workforce is in jeopardy of a serious decline, and incentives to pursue rheumatology training, including help with graduate medical education funding, could provide critical relief, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Tumor necrosis factor inhibitors, a group of biologic drugs used to treat children with juvenile idiopathic arthritis, are not associated with a significantly increased risk of cancer, according to new research findings presented this week at the ACR/ARHP Annual Meeting in Washington.
Two new studies measure the prevalence of myocardial inflammation in RA patients without known cardiovascular disease, assess how it is associated with high disease activity and show how disease-modifying therapy may decrease this type of inflammation, according to new research findings presented this week at the ACR/ARHP Annual Meeting in Washington.
Giving severely depressed patients the arthritis drug celecoxib (Celebrex®) dramatically boosted the effectiveness of their antidepressant medication, a Loyola study has found.
Researchers at Hospital for Special Surgery found that a low-impact exercise program in senior centers in New York City’s Chinatown and Flushing, Queens communities helped decrease pain, improve mobility and enhance quality of life for many participants.
Hospital for Special Surgery, which has an Outpatient Center in Stamford, CT, recently conducted a survey to assess the musculoskeletal health needs of people in the local area. Arthritis was the most common diagnosed condition in the community, and falls were also a significant problem.
Patients could soon be diagnosed with early-stage arthritis several years before the onset of physical and irreversible symptoms, thanks to a new test developed by researchers at the University of Warwick. Led by Dr Naila Rabbani of Warwick Medical School, the researchers developed a test that can provide an early diagnosis of osteoarthritis (OA) and also distinguish this from early-stage rheumatoid arthritis (RA) and other self-resolving inflammatory joint disease.
The Latest in Cell Biology News
FDA Grants Breakthrough Therapy Designation for GENENTECH’S Actemra® (tocilizumab) in Giant Cell Arteritis, A form of vasculitis
Children with a history of food allergy have a high risk of developing asthma and allergic rhinitis during childhood as well. The risk increases with the number of food allergies a child might have. Research suggests that U.S. disease rates may be changing for the common childhood conditions asthma, allergic rhinitis and eczema.
Rheumatoid arthritis patients taking medications that inhibit interleukin-1beta (IL-1beta), a molecule that stimulates the immune system, are 300 times more likely to experience invasive Group A Streptococcal infections than patients not on the drug, according to University of California San Diego School of Medicine researchers. Their study, published August 19 in Science Immunology, also uncovers a critical new role for IL-1beta as the body’s independent early warning system for bacterial infections.
Researchers at Mayo Clinic have reported a causal link between senescent cells — cells that accumulate with age and contribute to frailty and disease — and osteoarthritis in mice.
A briefing featuring short presentations on key data shared at the 5th International Symposium on Focused Ultrasound. Experts will highlight clinical outcomes and advances in the use of focused ultrasound – a non-invasive therapeutic technology – to treat brain disorders, cancers, pain and hypertension. A Q&A and opportunity for interviews will follow.
Researchers at Hospital for Special Surgery have launched a study to determine if a treatment using stem cells could help people with painful knee arthritis. To evaluate safety and efficacy, investigators are currently recruiting patients with osteoarthritis, which comes from wear and tear on a joint.
With a goal of treating worn, arthritic hips without extensive surgery to replace them, scientists at Washington University School of Medicine in St. Louis have programmed stem cells to grow new cartilage on a 3-D template shaped like the ball of a hip joint. What’s more, using gene therapy, they have activated the new cartilage to release anti-inflammatory molecules to fend off a return of arthritis.
The bacteria in your gut do more than break down your food. They also can predict susceptibility to rheumatoid arthritis, suggests Veena Taneja, Ph.D., an immunologist at Mayo Clinic’s Center for Individualized Medicine. Dr. Taneja recently published two studies — one in Genome Medicine and one in Arthritis and Rheumatology — connecting the dots between gut microbiota and rheumatoid arthritis.
The American College of Rheumatology (ACR) praised the agency for recognizing the important role qualified clinical data registries (QCDRs) will play in the Merit-Based Incentive Payment System (MIPS) payment pathway, but expressed a number of concerns regarding the complexity and timing of requirements for small and solo practices, the absence of key cost data in the Resource Use category of MIPS, and the formidable barriers that exclude many rheumatologists from participating in the Alternative Payment Model (APM) track.
Case reports on 13 cancer patients suggest that a small number of cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at some higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns Hopkins Medicine researchers.
Experts from the American College of Rheumatology (ACR), Food and Drug Administration (FDA), and other leading national healthcare groups spoke about the emerging biosimilars market, including key policy and regulatory questions for patients, providers and the healthcare system, during a national policy briefing held today by the nonpartisan Alliance for Health Reform.
In the fight to end opioid abuse, Blue Cross Blue Shield in at least two states is denying coverage of a proven nonopioid treatment for chronic pain
Researchers at the University of California San Diego School of Medicine, with colleagues in Pennsylvania and China, report that not only are there distinct differences in key cellular processes and molecular signatures between rheumatoid arthritis (RA) and osteoarthritis (OA) but, more surprisingly, there are joint-specific differences in RA. The findings help explain why drugs treating RA vary in effect and provide a potential new template for precisely targeting treatment for each and every ailing joint.
AMGA Foundation today announced the release of the Best Practices in Managing Patients with Rheumatoid Arthritis Compendium. The compendium includes case studies from medical groups, independent practice associations, academic practices, and integrated delivery systems that have incorporated the management of rheumatoid arthritis (RA) into their chronic care models.
Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn’t just work by inhibiting its target protein, TNF, but by enhancing a particular function of TNF in rheumatoid arthritis patients. The study, “Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis,” which will be published online June 6 in The Journal of Experimental Medicine, may help explain the divergent efficacies of different TNF-targeting drugs.
Click to visit the Aging Channel
The use of arthroscopic hip surgery for pain relief has increased dramatically in the past decade. A study looking at patient data bases in Florida and California finds it may not be the best option, especially if a patient has arthritis or is over 60. Many needed a hip replacement within two years.
click to view today's top stories
The Arthritis Foundation and Takeda Pharmaceuticals U.S.A., Inc. (Takeda) launched Let’s Speak Gout, a program based on new joint research, that offers tools for health care professionals and patients to make more effective gouty arthritis (“gout”) management a priority.
click to view today's top stories
click to see today's top stories
click to see today's top stories
Pinellas County a Model for Mosquito-Borne Disease Surveillance, Scientists Unravel the Genetic Evolution of Zika Virus, Worm Infection Counters Inflammatory Bowel Disease and more in the Infectious Diseases News Source
The ACR has issued an official statement regarding the FDA's approval of Inflectra (infliximab-dyyb), a biosimilar to Remicade. Inflectra is the first biosimilar to receive approval in the U.S. for the treatment of rheumatic diseases, including rheumatoid arthritis and psoriatic arthritis.
Research funding awarded to evaluate the effectiveness of disease-specific outcomes of patients using biologic therapies.
Despite chronic inflammation and an elevated risk of heart disease, patients with rheumatoid arthritis (RA) are not at increased risk for cardiovascular complications or death after surgery, compared to patients with similar characteristics without RA, reports a study in Anesthesia & Analgesia.
Juvenile idiopathic arthritis, or JIA, is the most common form of childhood arthritis. It appears to be an autoimmune disease, caused by antibodies attacking certain proteins in a person’s own tissue. But no “autoantigens”—the proteins triggering an immune attack—have been linked to JIA.
The study evaluated 612 questionnaires from patients to determine their knowledge about gout and if they knew what their uric acid numerical treatment goal was.
A new study led by scientists at The Scripps Research Institute shows how dangerous autoimmune responses, seen in diseases such as lupus and multiple sclerosis, might be “dialed down” without compromising the immune system’s ability to fight viruses and bacteria.
New research from The University of Manchester and the Babraham Institute has revealed how gaps between genes interact to influence the risk of acquiring diseases such as arthritis and type 1 diabetes.
Study results show that physicians are underutilizing methotrexate, the leading drug for rheumatoid arthritis (RA), or not keeping patients on the drug long enough before switching them to more expensive biologic drug options.
Osteoarthritis (OA) is one of the leading causes of disability in adults in the United States and knee OA specifically is ranked within the top 10 non-communicable diseases for global disability-adjusted life years.
The American College of Rheumatology (ACR) released its 2015 Guideline for the Treatment of Rheumatoid Arthritis (RA) during the 2015 ACR/ARHP Annual Meeting in San Francisco. The guideline is designed for use by both rheumatologists and other clinicians for pharmacologic treatment decisions in commonly encountered clinical situations.
Findings from a new study conducted by researchers from Hospital for Special Surgery suggest that lower socioeconomic status at the community level significantly increases the risk of pain and poor function following a knee replacement.
Rheumatoid arthritis patients are twice as likely as the average person to develop heart disease, but a new study shows that efforts to prevent heart problems and diagnose and treat heart disease early may be paying off. Despite the heightened danger, deaths from cardiovascular disease among people with rheumatoid arthritis are declining, the research found. The study was among Mayo Clinic research being presented at the American College of Rheumatology’s annual meeting in San Francisco.
Injecting ozone gas into the knee reduces pain and improves functioning and quality of life in people with knee osteoarthritis, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco
People with well-controlled rheumatoid arthritis who change anti-TNF inhibitors due to non-medical reasons — such as increased copay, change of insurance, job loss, or other economic factors — are at a higher risk to develop increased symptoms and higher disease activity as well as an increased utilization of health care resource use, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Francisco.
Injections of corticosteroids in the knee joints appear to be safe, but not effective, according to the findings of a two-year clinical trial presented this week at the American College of Rheumatology Annual Meeting in San Francisco.
People diagnosed with rheumatoid arthritis after the year 2000 don’t have as much of an increased risk of death as people diagnosed before 2000, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco. This, suggests the researchers involved in the study, is likely due to better treatments that focus on eradicating inflammation – a major contributor to the increased risk of death in RA
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right